A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Polymer-coated nanoparticles loaded with therapeutic drugs show significant promise for cancer treatment, including ovarian ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

She believed that had she had a CA125 blood test earlier - CA125 is a protein in the blood and can be raised in women with ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...